Drug intelligence / Profile preview

acetohydroxamic acid

Development stage: Approved
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

Acetohydroxamic acid is a synthetic urea derivative and urease inhibitor used as an adjunct therapy for chronic urinary tract infections caused by urea-splitting bacteria. These bacteria increase ammonia levels in the urine, leading to the formation of struvite kidney stones. Acetohydroxamic acid works by reversibly inhibiting the bacterial enzyme urease, thereby reducing the hydrolysis of urea and subsequent ammonia production. This results in lower urinary pH and ammonia levels, which slows kidney stone growth and enhances the effectiveness of antibiotics against these infections. It does not have direct antibacterial activity or directly acidify urine[1][2][3][4][6][8].

Brand names: Lithostat
Other names: N-hydroxyacetamideAHA

Targets

Urease

Beyond the preview

Go deeper on acetohydroxamic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on acetohydroxamic acid.

Explore the full profile